Merck & Co. (MSD)

What they make

1 input Merck & Co. (MSD) supplies

Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.

Intelligence

What's known

Sourced claims about this company's role in supply chains, chokepoints, concentration, incidents, dual-use connections.

• Chokepoint2024

  Merck holds near-monopolies on several of the vaccines that protect against some of humanity's most serious infectious threats. Its Gardasil is, in practice, the dominant (often the only widely available) vaccine against human papillomavirus — the virus that causes most cervical cancers — so a huge share of the world's cervical-cancer prevention runs through one company's production. Merck is likewise one of very few makers of the combined measles-mumps-rubella (MMR) and chickenpox (varicella) vaccines that underpin childhood immunization, and a key supplier of pneumococcal vaccines. That concentration means protection against cervical cancer, measles and other diseases for much of the planet depends on the manufacturing reliability of a single firm — and vaccine production is notoriously slow, biologically finicky and hard to surge. As with the contrast-media, sterile-injectable and antivenom chokepoints elsewhere in this radar, the supply of a life-saving biological rests on very few makers, so a manufacturing disruption or a decision to deprioritize a low-margin vaccine can ripple into shortages of protection against deadly diseases worldwide. [verify: Cervarix exited US 2016; Gardasil9 near-monopoly HPV; Merck key MMR/varicella maker]

  Merck & Co., Inc. (MRK) ↗

• Concentration2024

  Merck's own fortunes are extraordinarily concentrated in a single drug: Keytruda, its cancer immunotherapy, became the best-selling pharmaceutical in the world, accounting for a very large share of Merck's revenue. That makes the company itself a concentration risk — one patent-protected molecule generating a huge chunk of its sales — and it faces a looming "patent cliff" as Keytruda's exclusivity erodes later this decade, opening the door to cheaper biosimilar competition. The scramble to replace that revenue (through new oncology drugs, acquisitions and a subcutaneous reformulation to extend Keytruda's patent life) is the central strategic drama for one of the world's largest drugmakers. It's a reminder that concentration risk in pharma runs in two directions: society depends on a few firms for critical medicines, and those firms in turn often depend on a few blockbuster products — so the financial health of a company that supplies the world's vaccines and cancer drugs can itself hinge on the patent timeline of a single molecule.

  Merck & Co., Inc. (MRK) ↗

• Origin2024

  There are two companies called Merck, and which one "Merck" means depends on where you are — a quirk born of war. The original Merck began in Darmstadt, Germany in the 17th century and is today Merck KGaA, a global science-and-technology company. Its American subsidiary, set up in the late 1800s, was seized by the U.S. government during World War I as enemy property and became an independent American company — Merck & Co. The two have been entirely separate ever since, and they fight over the name: in the United States and Canada, the American firm uses "Merck" while the German original must operate as "EMD" or "Merck KGaA"; everywhere else, it's reversed, and the American company goes by "MSD." So a single famous pharmaceutical name actually denotes two unrelated multinationals, split by a century-old wartime expropriation, each forced to use a different name in the other's home turf. It's one of the most consequential brand-versus-ownership tangles in business — a reminder that even a company's name can be a geopolitical artifact, and that the "Merck" on a vaccine in New York and the "Merck" on a lab reagent in Berlin are not the same company at all.

  Merck & Co., Inc. (MRK) ↗